Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — Actithera […]
Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
Exclusive license via Yeda to two Weizmann Institute patent families from Prof. Nir London’s lab, a leader in covalent drug design Site-specific, durable and traceless protein radiolabeling approaches intended to enhance tumor selectivity and retention in radiopharmaceuticals Integration into Actithera’s platform to support design of next-generation radioligand therapies across oncology indications Cambridge, MA and Oslo, […]